Biofrontera (BFRI) Gains from Investment Securities (2020 - 2025)
Biofrontera's (BFRI) quarterly Gains from Investment Securities came in at -$482000.0 in Q4 2025, down 37.32% year-on-year from -$769009.1 in Q4 2024, and down 269.12% quarter-over-quarter from $285000.0 in Q3 2025.
Biofrontera (BFRI) Gains from Investment Securities (2020 - 2025) Analysis & Trends
Biofrontera's Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$482000.0 for Q4 2025.
- On a quarterly basis, Gains from Investment Securities fell 37.32% year-over-year to -$482000.0 in Q4 2025; TTM through Dec 2025 was -$898000.0, a 46.55% increase from a year earlier, with the FY2025 full-year figure at -$899000.0, up 46.49% from the prior year.
- Gains from Investment Securities retreated to -$482000.0 in Q4 2025 per BFRI's latest filing, from $285000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $11.1 million in Q4 2021 and bottomed at -$8.7 million in Q1 2022.
- The 5-year median for Gains from Investment Securities is -$275500.0 (2023), against an average of -$868055.6.
- Across the five-year window, Gains from Investment Securities surged 11429.59% in 2021 and plunged 5538.0% in 2024, its largest moves.
- Year by year, Gains from Investment Securities stood at $11.1 million in 2021, then slumped by 97.3% to $300000.0 in 2022, then sank by 2285.33% to -$6.6 million in 2023, then jumped by 94.65% to -$351000.0 in 2024, then tumbled by 37.32% to -$482000.0 in 2025.
- Per Business Quant, the three latest BFRI Gains from Investment Securities figures stand at -$482000.0 (Q4 2025), $285000.0 (Q3 2025), and -$153000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Biofrontera | 10.78 Mn | 4.37 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -482,000.00 |
| Dec 31, 2025 | -482,000.00 |
| Sep 30, 2025 | 285,000.00 |
| Sep 30, 2025 | 285,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -548,000.00 |
| Mar 31, 2025 | -548,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | -5.44 Mn |
| Jun 30, 2024 | -5.44 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Dec 31, 2023 | -6.56 Mn |
| Dec 31, 2023 | -6.56 Mn |
| Sep 30, 2023 | -598,000.00 |
| Sep 30, 2023 | -598,000.00 |